Andrulis Slaps Celgene With Method-Of-Use Patent Suit

Andrulis Pharmaceuticals has slapped Celgene with a lawsuit claiming its competitor illegally encourages physicians to prescribe a combination of cancer drugs covered by its method patent. Celgene promotes the use of its cancer drugs Thalomid (thalidomide) and Revlimid (lenalidomide) in combination with GlaxoSmithKline’s Alkeran (melphalan), directly infringing one or more claims of Andrulis ’346 patent, the suit claims.
Washington Drug Letter